NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/17/2026
Back to search
Official data from USPTO
GENFAR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
02/17/2026
Trademark type
Combined
Nice classes
5, 35
Filing date
04/17/2024
Registration date
02/17/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/17/2026
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
99
Owner location
Bogotá D.C., CO
Examiner
ABID, NABEELA
Law office
O50
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized word "GENFAR" in red.
Holders and representatives
Holders
Genfar S.A.
Representatives
Stacy J. Grossman Law Office of Stacy J. Grossman PLLC
Technical classification
Nice Classes
Class 5Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products of chemical synthesis and biologics for human use for the prevention and treatment of acute and chronic diseases for different age groups relating to the nervous systemcardiovascular systemrespiratory systemendocrine systemdigestive systemgenitourinary systemmusculoskeletal systemsensory systemshematopoietic systemimmune system; Pharmaceutical products in the form of prescription and non-prescription drugspillstabletscapsulesgranulatessachetsdropssyrupsinjectablesinhalerspatchescreamsgelssuppositoriesovulesimplantsany pharmaceutical form that allows adequate administration of the drugall for the prevention and treatment of chronic diseases for different age groups relating to the nervous systemcardiovascular systemrespiratory systemendocrine systemdigestive systemgenitourinary systemmusculoskeletal systemsensory systemshematopoietic systemimmune system; Pharmaceutical preparations for the treatment and prevention of acute and chronic diseases of the nervouscardiovascularrespiratoryendocrinedigestivegenitourinarymusculoskeletalsensoryhematopoieticimmune systems; drugs in the nature of pharmaceutical preparations for the treatment of infections caused by bacteriavirusesfungiparasitesother germs; Chemical and biological preparations for medical and pharmaceutical uses for the treatment and prevention of acute and chronic diseases relating to infectious diseasesneurological diseasespsychiatric conditionsendocrinological diseasesdigestive diseasescardiovascular diseasesrenal diseasesrespiratory diseasessense organ diseasesmusculoskeletal diseasesmale and female reproductive organ diseases relating to contraceptivesimmunological diseasesallergic conditionsinflammatory diseasesskin and adnexa dermatological diseasesoncological conditionshematopoietic diseases; Vaccines; Baby food; Medical plasters; Dressing materialsmedical dressings; Disinfectants; Vitamins; Vitamin preparations; Food supplements for medicinal purposes; Mineral food supplements for medicinal purposes; Nutritional supplements; Herbal preparations for medicinal purposes; Food supplements containing proteincarbohydratesfatfiber and micronutrients in the form of vitaminsmineral supplementsamino acid preparations for medicinal purposes and fatty acids for medicinal purposes
Class 35
Business representative services in the nature of independent sales representativesimport-export agenciesall in the fields of pharmaceutical productspharmaceutical preparationsmedicines for human and veterinary healthantibioticsdermatologicalophthalmologicalotological and homeopathic medicinesmedicines for animal health and other medicines for the defense and protection of human and veterinary health
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/17/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/30/2025
PUBO
PUBLISHED FOR OPPOSITION
12/30/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/24/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/03/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
12/03/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/03/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
12/03/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/02/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/26/2025
GNRT
NON-FINAL ACTION E-MAILED
11/26/2025
CNRT
NON-FINAL ACTION WRITTEN
11/26/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/25/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/25/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/25/2025
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/09/2025
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/09/2025
CNSI
SUSPENSION INQUIRY WRITTEN
09/09/2025
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/29/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/28/2025
GNSL
LETTER OF SUSPENSION E-MAILED
01/28/2025
CNSL
SUSPENSION LETTER WRITTEN
01/28/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/15/2025
GNRT
NON-FINAL ACTION E-MAILED
01/15/2025
CNRT
NON-FINAL ACTION WRITTEN
01/15/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/14/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/14/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/14/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/30/2024
GNRT
NON-FINAL ACTION E-MAILED
10/30/2024
CNRT
NON-FINAL ACTION WRITTEN
10/30/2024
DOCK
ASSIGNED TO EXAMINER
10/30/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/02/2024
NWAP
NEW APPLICATION ENTERED
04/17/2024
Continuous trademark protection
Get notified about every new filing that threatens GENFAR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.